The utility of α-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature

Biomarkers in Medicine

Volumn 10, Issue 1, 2016, Pages 19-34

  Simonsen, Anja Hviid ^a   Kuiperij, Bea ^b   El Agnaf, Omar Mukhtar Ali ^c   Engelborghs, Sebastian ^d   Herukka, Sanna Kaisa ^e   Parnetti, Lucilla ^f   Rektorova, Irena ^g   Vanmechelen, Eugeen ^h   Kapaki, Elisabeth ⁱ   Verbeek, Marcel ^b   Mollenhauer, Brit ^j  

^a University of Copenhagen   (Denmark)

^b RADBOUD UNIVERSITY   (Netherlands)

^c HAMAD BIN KHALIFA UNIVERSITY   (Qatar)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

^f UNIVERSITY OF PERUGIA   (Italy)

^g MASARYK UNIVERSITY   (Czech Republic)

^h ADX NEUROSCIENCES   (Belgium)

ⁱ UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^j UNIVERSITY OF GÖTTINGEN   (Germany)

more..

Author keywords

biomarker; CSF; diagnosis; ELISA; Parkinson's disease; synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; OLIGOMER; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BODY FLUID; CEREBROSPINAL FLUID; DEGENERATIVE DISEASE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE MUTATION; HUMAN; IMMUNOASSAY; PARKINSON DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; SALIVA LEVEL; SHY DRAGER SYNDROME; SYSTEMATIC REVIEW; ANIMAL; CLINICAL CHEMISTRY; GENETICS; NEURODEGENERATIVE DISEASES;

ALPHA-SYNUCLEIN; ANIMALS; BIOMARKERS; CLINICAL CHEMISTRY TESTS; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 84951806008     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/BMM.14.105     Document Type: Article

References (94)

1. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol. 119(6), 703-713 (2010).
2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55(3), 181-184 (1992).
3. El-Agnaf OM, Salem SA, Paleologou KE et al. Alphasynuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 17(13), 1945-1947 (2003).
4. Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG. Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark. Med. 4(5), 683-699 (2010).
5. Ueda K, Saitoh T, Mori H. Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-A beta component of Alzheimer's disease amyloid. Biochem. Biophys. Res. Commun. 205(2), 1366-1372 (1994).
6. Campion D, Martin C, Heilig R et al. The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease. Genomics 26(2), 254-257 (1995).
7. Mollenhauer B, Cullen V, Kahn I et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 213(2), 315-325 (2008).
8. Tokuda T, Salem SA, Allsop D et al. Decreased alphasynuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349(1), 162-166 (2006).
9. Van Geel WJ, Abdo WF, Melis R, Williams S, Bloem BR, Verbeek MM. A more efficient enzyme-linked immunosorbent assay for measurement of alpha-synuclein in cerebrospinal fluid. J. Neurosci. Methods 168(1), 182-185 (2008).
10. Tokuda T, Qureshi MM, Ardah MT et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75(20), 1766-1772 (2010).
11. Parnetti L, Chiasserini D, Bellomo G et al. Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov. Disord. 26(8), 1428-1435 (2011).
12. Parnetti L, Farotti L, Eusebi P et al. Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson's disease. Front. Aging Neurosci. 6, 53 (2014).
13. Reesink FE, Lemstra AW, Van Dijk KD et al. CSF alphasynuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. J. Alzheimers Dis. 22(1), 87-95 (2010).
14. Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM. CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol. Aging 33(2), 430.e1-e3 (2012).
15. Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J. Clin. Neurol. 7(4), 215-222 (2011).
16. Aasly JO, Johansen KK, Bronstad G et al. Elevated levels of cerebrospinal fluid alpha-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front. Aging Neurosci. 6, 248 (2014).
17. Tinsley RB, Kotschet K, Modesto D et al. Sensitive and specific detection of alpha-synuclein in human plasma. J. Neurosci. Res. 88(12), 2693-2700 (2010).
18. Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M, Vives F. Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment. Mov. Disord. 25(4), 489-493 (2010).
19. Tateno F, Sakakibara R, Kawai T, Kishi M, Murano T. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis. Assoc. Disord. 26(3), 213-216 (2012).
20. Brighina L, Prigione A, Begni B et al. Lymphomonocyte alpha-synuclein levels in aging and in Parkinson disease. Neurobiol. Aging. 31(5), 884-885 (2010).
21. Su E, Bell MJ, Wisniewski SR et al. alpha-Synuclein levels are elevated in cerebrospinal fluid following traumatic brain injury in infants and children: the effect of therapeutic hypothermia. Dev. Neurosci. 32(5-6), 385-395 (2010).
22. Laske C, Fallgatter AJ, Stransky E, Hagen K, Berg D, Maetzler W. Decreased alpha-synuclein serum levels in patients with Lewy body dementia compared with Alzheimer's disease patients and control subjects. Dement. Geriatr. Cogn. Disord. 31(6), 413-416 (2011).
23. Wennstrom M, Surova Y, Hall S et al. Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 8(1), e53250 (2013).
24. Wang H, Wang K, Xu W et al. Cerebrospinal fluid alphasynuclein levels are elevated in multiple sclerosis and neuromyelitis optica patients during replase. J. Neurochem. 122(1), 19-23 (2012).
25. Bidinosti M, Shimshek DR, Mollenhauer B et al. Novel onestep immunoassays to quantify alpha-synuclein: applications for biomarker development and high-throughput screening. J. Biol. Chem. 287(40), 33691-33705 (2012).
26. Emmanouilidou E, Elenis D, Papasilekas T et al. Assessment of alpha-synuclein secretion in mouse and human brain parenchyma. PLoS ONE 6(7), e22225 (2011).
27. Lee HJ, Bae EJ, Jang A et al. Enzyme-linked immunosorbent assays for alpha-synuclein with species and multimeric state specificities. J. Neurosci. Methods 199(2), 249-257 (2011).
28. Kovacs GG, Wagner U, Dumont B et al. An antibody with high reactivity for disease-associated alpha-synuclein reveals extensive brain pathology. Acta Neuropathol. 124(1), 37-50 (2012).
29. Ohrfelt A, Grognet P, Andreasen N et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci. Lett. 450(3), 332-335 (2009).
30. Kruse N, Vanmechelen E, Schlossmacher MG et al. Sensitive multiplex quantification of alpha-Synuclein, DJ-1, beta-Amyloid 1-42 and Tau protein in human biological fluids based on chemiluminescence detection. Neurodegener. Dis. 11(Suppl. 1) (2013).
31. Kruse N, Schulz-Schaeffer WJ, Schlossmacher MG, Mollenhauer B. Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of alpha-synuclein and other proteins in cerebrospinal fluid. Methods 56(4), 514-518 (2012).
32. Kasuga K, Tokutake T, Ishikawa A et al. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 81(6), 608-610 (2010).
33. Hong Z, Shi M, Chung KA et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133(Pt 3), 713-726 (2010).
34. Mollenhauer B, Trautmann E, Taylor P et al. Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci. Lett. 532, 44-48 (2013).
35. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10(3), 230-240 (2011).
36. Korff A, Liu C, Ginghina C, Shi M, Zhang J, Alzheimer's Disease Neuroimaging I. alpha-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. J. Alzheimers Dis. 36(4), 679-688 (2013).
37. Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J. CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer's disease. Acta Neuropathol. 126(5), 683-697 (2013).
38. Hall S, Ohrfelt A, Constantinescu R et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or Parkinsonian disorders. Arch. Neurol. 69(11), 1445-1452 (2012).
39. Slaets S, Vanmechelen E, Le Bastard N et al. Increased CSF alpha-synuclein levels in Alzheimer's disease: correlation with tau levels. Alzheimers Dement. 10(5, Suppl.), S290-S298 (2014).
40. Kang JH, Irwin DJ, Chen-Plotkin AS et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA neurol. 70(10), 1277-1287 (2013).
41. Mondello S, Constantinescu R, Zetterberg H, Andreasson U, Holmberg B, Jeromin A. CSF alpha-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. Parkinsonism. Relat. Disord. 20(4), 382-387 (2014).
42. El-Agnaf OM, Irvine GB. Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins. J. Struct. Biol. 130(2-3), 300-309 (2000).
43. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37(4), 583-595 (2003).
44. Paleologou KE, Kragh CL, Mann DM et al. Detection of elevated levels of soluble alpha-synuclein oligomers in postmortem brain extracts from patients with dementia with Lewy bodies. Brain 132(Pt 4), 1093-1101 (2009).
45. Klucken J, Outeiro TF, Nguyen P, Mclean PJ, Hyman BT. Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging. FASEB J. 20(12), 2050-2057 (2006).
46. El-Agnaf OM, Salem SA, Paleologou KE et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20(3), 419-425 (2006).
47. Fujiwara H, Hasegawa M, Dohmae N et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell. Biol. 4(2), 160-164 (2002).
48. Anderson JP, Walker DE, Goldstein JM et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281(40), 29739-29752 (2006).
49. Games D, Seubert P, Rockenstein E et al. Axonopathy in an alpha-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminaltruncated alpha-synuclein. Am. J. Pathol. 182(3), 940-953 (2013).
50. El-Agnaf OM, Walsh DM, Allsop D. Soluble oligomers for the diagnosis of neurodegenerative diseases. Lancet Neurol. 2(8), 461-462 (2003).
51. Bartels T, Choi JG, Selkoe DJ. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477(7362), 107-110 (2011).
52. Gorostidi A, Bergareche A, Ruiz-Martinez J et al. Alphasynuclein levels in blood plasma from LRRK2 mutation carriers. PLoS ONE 7(12), e52312 (2012).
53. Lindersson E, Beedholm R, Hojrup P et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J. Biol. Chem. 279(13), 12924-12934 (2004).
54. Unterberger U, Lachmann I, Voigtlander T et al. Detection of disease-associated alpha-synuclein in the cerebrospinal fluid: a feasibility study. Clin. Neuropathol. 33(5), 329-334 (2014).
55. Okochi M, Walter J, Koyama A et al. Constitutive phosphorylation of the Parkinson's disease associated alphasynuclein. J. Biol. Chem. 275(1), 390-397 (2000).
56. Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 8(5), 657-663 (2005).
57. Foulds PG, Mitchell JD, Parker A et al. Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J. 25(12), 4127-4137 (2011).
58. Wang Y, Shi M, Chung KA et al. Phosphorylated alphasynuclein in Parkinson's disease. Sci. Transl. Med. 4(121), 121ra120 (2012).
59. Fernandez E, Garcia-Moreno JM, Martin De Pablos A, Chacon J. May the evaluation of nitrosative stress through selective increase of 3-nitrotyrosine proteins other than nitroalbumin and dominant tyrosine-125/136 nitrosylation of serum alphasynuclein serve for diagnosis of sporadic Parkinson's disease? Antioxid. Redox. Signal. 19(9), 912-918 (2013).
60. Chavez J, Bajrami B, Copeland M et al. Development of quantitative methods to measure alpha-synuclein and related subspecies in CSF as candidate biomarkers for Parkinson's disease progression. Neurodegener. Dis. 11(Suppl. 1), (2013).
61. Van Dijk KD, Bidinosti M, Weiss A, Raijmakers P, Berendse HW, Van De Berg WD. Reduced alpha-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity. Eur. J. Neurol. 21(3), 388-394 (2014).
62. Blennow K, Wallin A, Hager O. Low frequency of postlumbar puncture headache in demented patients. Acta Neurol. Scand. 88(3), 221-223 (1993).
63. Braak H, Del Tredici K, Rub U, De Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24(2), 197-211 (2003).
64. Barbour R, Kling K, Anderson JP et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener. Dis. 5(2), 55-59 (2008).
65. Scherzer CR, Grass JA, Liao Z et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc. Natl Acad. Sci. USA 105(31), 10907-10912 (2008).
66. Mollenhauer B, Trautmann E, Otte B et al. alpha-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J. Neural. Transm. 119(7), 739-746 (2012).
67. Mata IF, Shi M, Agarwal P et al. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch. Neurol. 67(11), 1350-1356 (2010).
68. Besong-Agbo D, Wolf E, Jessen F et al. Naturally occurring alpha-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 80(2), 169-175 (2013).
69. Devic I, Hwang H, Edgar JS et al. Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 134(Pt 7), e178 (2011).
70. Bolstad N, Warren DJ, Nustad K. Heterophilic antibody interference in immunometric assays. Best Pract. Res. Clin. Endocrinol. Metab. 27(5), 647-661 (2013).
71. Sehlin D, Sollvander S, Paulie S et al. Interference from heterophilic antibodies in amyloid-beta oligomer ELISAs. J. Alzheimers Dis. 21(4), 1295-1301 (2010).
72. Bruggink KA, Kuiperij HB, Ekholm-Pettersson F, Verbeek MM. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 77(5), 510; author reply 510-511 (2011).
73. Kasuga K, Nishizawa M, Ikeuchi T. alpha-synuclein as CSF and blood biomarker of dementia with Lewy bodies. Int. J. Alzheimers Dis. 2012, 437025 (2012).
74. Kapaki E, Paraskevas GP, Emmanouilidou E, Vekrellis K. The diagnostic value of CSF alpha-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease. PLoS ONE 8(11), e81654 (2013).
75. Teunissen CE, Tumani H, Bennett JL et al. Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker studies. Mult. Scler. Int. 2011, 246412 (2011).
76. Vakharia VN, Lote H. Introduction of Sprotte needles to a single-centre acute neurology service: before and after study. JRSM Short Rep. 3(12), 82 (2012).
77. Del Campo M, Mollenhauer B, Bertolotto A et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark. Med. 6(4), 419-430 (2012).
78. Noguchi-Shinohara M, Tokuda T, Yoshita M et al. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res. 1251, 1-6 (2009).
79. Mignini F, Bronzetti E, Felici L et al. Dopamine receptor immunohistochemistry in the rat choroid plexus. J. Auton. Pharmacol. 20(5-6), 325-332 (2000).
80. Wennstrom M, Londos E, Minthon L, Nielsen HM. Altered CSF orexin and alpha-synuclein levels in dementia patients. J. Alzheimers. Dis. 29(1), 125-132 (2012).
81. Kang JE, Lim MM, Bateman RJ et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326(5955), 1005-1007 (2009).
82. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 68(9), 666-669 (2007).
83. Spies PE, Slats D, Rikkert MG, Tseng J, Claassen JA, Verbeek MM. CSF alpha-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid beta in humans. Neurosci. Lett. 504(3), 336-338 (2011).
84. Spies PE, Melis RJ, Sjogren MJ, Rikkert MG, Verbeek MM. Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. J. Alzheimers Dis. 16(2), 363-369 (2009).
85. Shi M, Bradner J, Hancock AM et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 69(3), 570-580 (2011).
86. Herbert MK, Aerts MB, Beenes M et al. CSF neurofilament light chain but not FLT3 ligand discriminates Parkinsonian disorders. Front Neurol. 6, 91 (2015).
87. Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol. Aging 28(5), 742-747 (2007).
88. Giasson BI, Forman MS, Higuchi M et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300(5619), 636-640 (2003).
89. Shi M, Furay AR, Sossi V et al. DJ-1 and alphaSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol. Aging 33(4), 836 e835-e837 (2012).
90. Mollenhauer B, Trautmann E, Sixel-Doring F et al. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology 81(14), 1226-1234 (2013).
91. Parkinson Progression Marker I. The Parkinson Progression Marker Initiative (PPMI). Prog. Neurobiol. 95(4), 629-635 (2011).
92. Jellinger KA, Attems J. Neuropathological evaluation of mixed dementia. J. Neurol. Sci 257(1-2), 80-87 (2007).
93. Slaets S, Le Bastard N, Theuns J et al. Amyloid pathology influences abeta1-42 cerebrospinal fluid levels in dementia with lewy bodies. J. Alzheimers Dis. 35(1), 137-146 (2013).
94. Parnetti L, Castrioto A, Chiasserini D et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat. Rev. Neurol. 9(3), 131-140 (2013).